Replies to post #127460 on Biotech Values

[genisi]

the study was also a longer duration (24 weeks) then past approved PAH therapies (12 or 16)

I haven't seen Gleevec' efficacy data over time but could well be that with longer dosing they improve.

I doubt much impact on IV/sub-q use

I'd say also on inhaled.